Evaluation of Memorial Sloan- Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma

Róisín O’Cearbhaill is a medical oncologist at Memorial Sloan Kettering Cancer Center where she serves as the Clinical Director, Solid Tumor Malignancies, Cellular Therapeutics

Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous

Red blood cell distribution width as a simple negative prognostic factorin patients with diffuse large B-cell lymphoma: A retrospective

Skipets sjødyktighet, sikkerhet og drift: Studenten skal lese og forstå publikasjoner, bruke terminologi, beskrive prosedyrer og forebyggende tiltak, samt innhente og tolke krav

Patients (n = 300) over the age of 18 years, with a recent diagnosis of breast cancer, colorectal cancer, lymphoma, prostate cancer or testicle cancer and scheduled for ad-

32 Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France; 33 Department of Psychiatry and Psychotherapy, University Medical Center Göttingen,

Cardiff University, UK Faramarz Samavati University of Calgary, CA Anthony Santella. Sloan Kettering Institute, US

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with